001053899 001__ 1053899
001053899 005__ 20260130162812.0
001053899 0247_ $$2doi$$a10.1093/neuonc/noaf201.0170
001053899 0247_ $$2ISSN$$a1522-8517
001053899 0247_ $$2ISSN$$a1523-5866
001053899 037__ $$aFZJ-2026-01597
001053899 082__ $$a610
001053899 1001_ $$0P:(DE-HGF)0$$aPitarch-Abaigar, Carla$$b0
001053899 1112_ $$a7th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies$$cHonolulu$$d2025-11-20 - 2025-11-23$$gWFNOS/SNO 2025$$wUSA
001053899 245__ $$aBIOM-82. GLIOBLASTOMA BEYOND THE ENHANCING TUMOR MARGINS: A LONGITUDINAL CASE STUDY COMPARING FET PET WITH MRI-BASED AI INFILTRATION MAPS
001053899 260__ $$c2025
001053899 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1769786547_19717
001053899 3367_ $$033$$2EndNote$$aConference Paper
001053899 3367_ $$2BibTeX$$aINPROCEEDINGS
001053899 3367_ $$2DRIVER$$aconferenceObject
001053899 3367_ $$2DataCite$$aOutput Types/Conference Abstract
001053899 3367_ $$2ORCID$$aOTHER
001053899 520__ $$aAbstractBACKGROUNDGlioblastoma is the most common malignant brain tumor, with rapid proliferation, diffuse infiltration, and poor prognosis. Imaging plays a central role in its diagnosis, treatment planning, and disease monitoring. Positron Emission Tomography with O-(2-[18F]fluoroethyl)-L-tyrosine (FET PET) depicts metabolically active tumor irrespective of the blood-brain barrier integrity. Here, we compare FET PET with AI-generated infiltration maps (AI-InfM) derived from multiparametric MRI (mpMRI - T1, T1Gd, T2, T2-FLAIR, DSC) to identify viable tumor beyond the enhancing tumor, potentially corresponding to early recurrence sites.METHODSWe identified a patient with a newly-diagnosed glioblastoma in a non resectable eloquent area. Pre-operative scans were acquired at baseline and two follow-up timepoints, during and post-treatment, at six-month intervals. Each scanning session comprised a 50-minute dynamic FET PET scan and mpMRI performed at Research Center Juelich, Germany. AI-InfM, based on Support Vector Machines, were trained following within-patient, self-normalized measures of heterogeneity across pre-operative mpMRI of treatment-naïve glioblastoma in a subset of the public UPENN-GBM dataset. AI-InfM were then generated for the identified patient and compared with FET PET visually and quantitatively using clinically-established measures, e.g., tumor-to-brain ratios (TBR).RESULTSAlthough FET PET showed no increased tracer uptake at baseline, the AI-InfM identified a region with elevated signal. This region exhibited increased uptake of FET in the first follow-up scan (TBRmax from 1.9 at baseline to 2.2 at follow-up), supporting the AI-InfM’s early prediction. After completion of adjuvant temozolomide therapy, the third scan denoted the predicted high-risk area with reduced tumor activity across FET PET, AI-InfM, and mpMRI.CONCLUSIONSOur findings indicate potential complementary value of FET PET and mpMRI-derived AI-InfM, for early recurrence identification. This case study underscores the potential to enhance early detection of tumor progression, by virtue of the infiltrative spread in glioblastoma, and warrants continued development and evaluation in a larger multi-institutional cohort.
001053899 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001053899 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001053899 7001_ $$0P:(DE-HGF)0$$aAdap, Sanyukta$$b1
001053899 7001_ $$0P:(DE-HGF)0$$aAkbari, Hamed$$b2
001053899 7001_ $$0P:(DE-HGF)0$$aFlinn, Alexandra$$b3
001053899 7001_ $$0P:(DE-Juel1)131794$$aShah, N Jon$$b4$$ufzj
001053899 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b5$$ufzj
001053899 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b6$$ufzj
001053899 7001_ $$0P:(DE-HGF)0$$aPease, Matthew$$b7
001053899 7001_ $$0P:(DE-HGF)0$$aGatson, Na Tosha$$b8
001053899 7001_ $$0P:(DE-HGF)0$$aLaViolette, Peter S$$b9
001053899 7001_ $$0P:(DE-HGF)0$$aDavatzikos, Christos$$b10
001053899 7001_ $$0P:(DE-HGF)0$$aParker, Jason$$b11
001053899 7001_ $$0P:(DE-Juel1)145110$$aLohmann, Philipp$$b12$$ufzj
001053899 7001_ $$0P:(DE-HGF)0$$aBakas, Spyridon$$b13
001053899 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noaf201.0170$$gVol. 27, no. Supplement_5, p. v43 - v43$$x1523-5866$$y2025
001053899 8564_ $$uhttps://academic.oup.com/neuro-oncology/article/27/Supplement_5/v43/8318208
001053899 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich$$b4$$kFZJ
001053899 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b5$$kFZJ
001053899 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b6$$kFZJ
001053899 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145110$$aForschungszentrum Jülich$$b12$$kFZJ
001053899 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001053899 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-11$$wger
001053899 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
001053899 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
001053899 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
001053899 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
001053899 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
001053899 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-11
001053899 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
001053899 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
001053899 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
001053899 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x0
001053899 980__ $$aabstract
001053899 980__ $$aEDITORS
001053899 980__ $$aVDBINPRINT
001053899 980__ $$aI:(DE-Juel1)INM-4-20090406
001053899 980__ $$aUNRESTRICTED